Last reviewed · How we verify
Metolazone 2.5 MG
At a glance
| Generic name | Metolazone 2.5 MG |
|---|---|
| Also known as | Standard of care including loop-diuretics |
| Sponsor | Clinica Alemana de Santiago |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload (PHASE4)
- Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg (PHASE1)
- Acetazolamide or Metolazone in Acute Heart Failure (NA)
- Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis (NA)
- AiDing Diuresis wIth Tolvaptan (ADD-IT) (PHASE1)
- Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metolazone 2.5 MG CI brief — competitive landscape report
- Metolazone 2.5 MG updates RSS · CI watch RSS
- Clinica Alemana de Santiago portfolio CI